French call to withdraw domperidone

A French medical journal has called for the gastric motility drug domperidone to be taken off the market because its risk of fatal cardiac arrhythmias outweighs its “modest” efficacy.

The suggestion was made by the editor of Prescrire after a study published by the journal suggested that domperidone caused as many as 120 premature deaths a year in France.

As a dopamine receptor antagonist, the drug was a “hidden neuroleptic”, the journal claimed, and it carried a recognised risk of QT interval prolongation.